18. May 2017

Chromogenic tissue transglutaminase activity assay



Zedira kits
 
Zedira logo

Transglutaminase-Newsletter | May 2017



ZediXclusive Tissue Transglutaminase Assay Kit (Z010)

Chromogenic TG2-assay launched!
Determination of TG2-activity in cuvetts or MTPs.

  • Chromogenic (measure at 525 nm)
  • Optimized for tissue transglutaminase (TG2)
  • Easy to use
  • Results within 30 min


Read more about Z010!

tissue transglutaminase assay Z010

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • Life Sciences 2019: Post-translational modifications and cell signalling

    17.03.2019 - 18.03.2019
    Nottingham, UK

  • 10th International meeting of the Society for research on the Cerebellum and Ataxias (SRCA)

    16.05.2019 - 17.05.2019
    Sheffield, UK

  • 18th International Celiac Disease Symposium ICDS

    04.09.2019 - 07.09.2019
    Paris, France